Healthcare Triangle, Inc. (HCTI) shareholders
Close on Nov 18, 2026Market cap $6.41MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Streeterville Management, LLC Joint filing with East West Capital, LLC (9.90%), Global Investors, LLC (9.90%) and 2 more | 821,286 | 9.90% | 13G (passive) | Feb 27, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of HCTI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Bank Of Montreal /Can/ | 20,000 | 0.13% | $36.20K | +10,000 | 0.00% |
| Geode Capital Management, LLC | 11,975 | 0.08% | $21.67K | −620 | 0.00% |
| UBS Group AG | 8,859 | 0.06% | $16.03K | −31,856 | 0.00% |
| Tower Research Capital LLC (TRC) | 1,314 | 0.01% | $2.38K | +520 | 0.00% |
| Vanguard Capital Management LLC | 859 | 0.01% | $1.56K | – | 0.00% |
| Barclays PLC | 310 | 0.00% | $561 | New | 0.00% |
| JPMorgan Chase & Co | 20 | 0.00% | $38 | New | 0.00% |
| Danske Bank A/S | 1 | 0.00% | $2 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 8 | 0M | 0.3% | 2 / 2 | 2 / 4 | 0M | 0M |
| Q1 2026 | 10 | 0M | 0.7% | 10 / 0 | 0 / 1 | 0M | 0M |
| Q4 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
7 funds held HCTI in Q2 2026, 7% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of HCTI | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 10,905 | 0.07% | $28.13K | 0.00% | May 31, 2026 |
| Invesco BuyBack AchieversTM ETF | 1,711 | 0.01% | $1.88K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 859 | 0.01% | $2.22K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 859 | 0.01% | $1.55K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 140 | 0.00% | $361 | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 35 | 0.00% | $90 | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -46 | -0.00% | -$83 | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Shibu Kizhakevilayil | Head of M&A, Director | 54,129 | 0.36% | Apr 2, 2025 |
| Lakshmanan Kannappan | Business Head | 324,180 | 2.16% | Apr 2, 2025 |
| Thyagarajan Ramachandran | Chief Financial Officer | 29,627 | 0.20% | Apr 2, 2025 |
| Securekloud Technologies, Inc. | 10% owner | 0 | – | Apr 2, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Thyagarajan Ramachandran Chief Financial Officer | Mar 31, 2025 | Other | +14,627 | – | – | 29,627 |
| Securekloud Technologies, Inc. 10% owner | Mar 31, 2025 | Other | −2,550,000 | – | – | 0 |
| Shibu Kizhakevilayil Head of M&A, Director | Mar 31, 2025 | Other | +34,129 | – | – | 54,129 |
| Lakshmanan Kannappan Business Head | Mar 31, 2025 | Other | +304,180 | – | – | 324,180 |
| Thyagarajan Ramachandran Chief Financial Officer | Nov 15, 2022 | Returned to company | +100,000 | $0.19 | $19.00K | 100,000 |
| Suresh Venkatachari Chief Executive Officer, Director, 10% owner | Jul 12, 2021 | Award | +6,000 | – | – | 6,000 |
| Suresh Venkatachari Chief Executive Officer, Director, 10% owner | Jul 12, 2021 | Award | +750,000 | – | – | 750,000 |
| Suresh Venkatachari Chief Executive Officer, Director, 10% owner | Jul 12, 2021 | Award | +6,000 | – | – | 6,000 |
| Lakshmanan Kannappan Head of Strategic Partnership, Director | May 27, 2020 | Returned to company | +200,000 | – | – | 200,000 |
| Suresh Venkatachari Chief Executive Officer, Director, 10% owner | May 8, 2020 | Award | +25,500,000 | $0.30 | $7.65M | 25,500,000 |
| Anand Kumar Vice President, Sales | Apr 27, 2020 | Returned to company | +150,000 | – | – | 150,000 |
| Shibu Kizhakevilayil Director | Apr 27, 2020 | Returned to company | +200,000 | – | – | 200,000 |
| Suresh Venkatachari Chief Executive Officer, Director, 10% owner | Apr 27, 2020 | Award | +750,000 | – | – | 750,000 |
| Suresh Venkatachari Chief Executive Officer, Director, 10% owner | Apr 27, 2020 | Award | +25,500,000 | $0.30 | $7.65M | 25,500,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Healthcare Triangle's stock actually held short. Settlement fails (shares not delivered on time) peaked at 442,611 shares on Sep 24, 2026 over the last 90 days.
See a number that looks wrong?